Fibronostics will be presenting 2 of our clinical studies at the International Liver Congress™ 2022 of the European Association for the Study of the Liver (EASL).
Fibronostics will be presenting 2 of our clinical studies at the International Liver Congress™ 2022 of the European Association for the Study of the Liver (EASL).
AASLD Poster: Comparing Non-Invasive Tools – LIVERFASt™, FIB-4 and Transient Elastography in Sequential and Combinatory Pathways for NAFLD.
ADA 2021: LIVERFAStTM Has Similar Performance to Liver Biopsy for the Screening of NASH Fibrosis in Type 2 Diabetes Mellitus (T2D).
Fibronostics_ADA-2021
EASL Poster: Noninvasive LIVERFASt transition rate to liver fibrosis is similar to that estimated with liver biopsy in NAFLD patients.
2021_EASL_ePOSTER_Transition-to-Fibrosis-vf-submitted
